BioCentury
ARTICLE | Clinical News

Lumiliximab regulatory update

January 21, 2008 8:00 AM UTC

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for lumiliximab to treat chronic lymphocytic leukemia (CLL). The anti- CD23 mAb, which ...